Novartis Aktie

122,40 EUR +0,55 EUR +0,45 %

18:16:27

STU

114,04 CHF +0,28 CHF +0,25 %

17:37:01

SWX

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.231,39 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

19.03.25GlobeNewswireNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

19.03.25Dow JonesPress Release: New Novartis Phase III data -2-

19.03.25Dow JonesPress Release: New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient popula...

13.03.25ZacksIs it the Right Time to Hold Alcon Stock in Your Portfolio Now?

12.03.25ZacksWhy Novartis (NVS) is a Top Value Stock for the Long-Term

07.03.25GlobeNewswireNovartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

03.03.25ZacksNovartis Gets CHMP Opinion for Label Expansion of Fabhalta

28.02.25ZacksAlcon Stock Gains From Innovation Despite Macroeconomic Troubles

28.02.25PR NewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25GlobeNewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25GlobeNewswireNovartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

28.02.25Dow JonesPress Release: Novartis oral Fabhalta(R) -2-

28.02.25Dow JonesPress Release: Novartis oral Fabhalta(R) (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

26.02.25BenzingaCourt Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

26.02.25ZacksAlcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

26.02.25ZacksAlcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

25.02.25ZacksHere's Why Novartis (NVS) is a Strong Momentum Stock

20.02.25ZacksWall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings

20.02.25PR NewswireBMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan

19.02.25PR NewswireCIBC introduces additional European Canadian Depositary Receipts ("CDRs")

11.02.25BenzingaNovartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal

11.02.25Financial TimesNovartis agrees $3bn deal to buy heart drug biotech from Blackstone

11.02.25GlobeNewswireNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

11.02.25Dow JonesPress Release: Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

06.02.25ZacksWhy Novartis (NVS) is a Top Momentum Stock for the Long-Term

06.02.25ZacksNovartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?

05.02.25ZacksHere's Why Novartis (NVS) is a Strong Value Stock

31.01.25ZacksNovartis Posts Q4 Earnings and Sales Beat, Shares Gain

31.01.25MotleyFoolNovartis Ag (NVS) Q4 2024 Earnings Call Transcript

31.01.25ZacksNovartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

31.01.25BenzingaNovartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries

31.01.25GlobeNewswireNovartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

31.01.25Dow JonesPress Release: Novartis continues strong momentum -5-

31.01.25Dow JonesPress Release: Novartis continues strong momentum -3-

31.01.25Dow JonesPress Release: Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

30.01.25BenzingaAbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?

28.01.25ZacksNovartis to Report Q4 Earnings: What's in the Offing?

23.01.25ZacksDo Options Traders Know Something About Alcon (ALC) Stock We Don't?

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.